Press Releases

Press Releases

DateTitle 
Dec 07, 2019
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy BURLINGAME, Calif. , Dec. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
Nov 08, 2019
  SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to
Nov 07, 2019
BURLINGAME, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that
Nov 05, 2019
BURLINGAME, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that
Nov 04, 2019
Event will provide a review of updated CPI-006 data from Phase 1/1b study and data on adenosine gene signature in renal cell cancer with ciforadenant presented at SITC 2019 BURLINGAME, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
Oct 29, 2019
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today
Oct 17, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Oct 03, 2019
CPI-006 data to be presented in oral presentation and poster presentation   BURLINGAME, Calif. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Aug 07, 2019
BURLINGAME, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the 2019 Wedbush
Aug 01, 2019
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today
Jul 24, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Jun 02, 2019
  Clinical and laboratory results support a new immuno-oncology approach with CPI-006  via activation of immune cells and the inhibition of adenosine production Initial Results demonstrated dose-dependent disease control in patients with advanced, refractory disease when administered as a
May 28, 2019
BURLINGAME, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the Jefferies 2019 Global
May 16, 2019
Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT BURLINGAME, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
May 09, 2019
Announces Initiation of Enrollment in Phase 1/1b Trial of ITK inhibitor CPI-818 Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the
May 01, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Mar 07, 2019
BURLINGAME, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and
Mar 05, 2019
BURLINGAME, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will present at the Cowen and
Feb 06, 2019
BURLINGAME, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and
Jan 30, 2019
BURLINGAME, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present updated data from its lead
Jan 28, 2019
BURLINGAME, Calif. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S.
Jan 10, 2019
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
Jan 08, 2019
Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms  now enrolling patients at U.S. sites CPI-006 in combination with CPI-444 targets multiple points in the adenosine pathway BURLINGAME, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.